Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling study to identify distinct subtypes in diffuse type gastric cancer

ABSTRACT: Gene expression profiling study to identify distinct subtypes in diffuse type gastric cancer

PROVIDER: PRJNA450596 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7014300_1.fastq.gz	Fastqsanger.gz
	SRR7014300_2.fastq.gz	Fastqsanger.gz
	SRR7014310_1.fastq.gz	Fastqsanger.gz
	SRR7014310_2.fastq.gz	Fastqsanger.gz
	SRR7014320_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 280

Similar Datasets

Gene expression profiling study to identify distinct subtypes in diffuse type gastric cancer

Project description:Although recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for handling diffuse type GC are identified. Here, we aim to identify a signature classifying high risk diffuse type GC. To identify molecular subtypes of diffuse type GC, we generated RNA-seq based transcriptome data, which were generated using normal mucosa and tumor cells from 140 fresh frozen tissues including diffuse type GCs (n = 107). Unsupervised hierarchical cluster analysis of the RNA-seq data revealed three distinct subgroups of GC. Based on these subtypes, we generated a signature reflecting the best characteristics of aggressive diffuse type GC. When estimating prognostic value, the signature showed a strong prediction ability and an independent clinical utility in diffuse type GC patients. Our signature represents a promising diagnostic tool for the identification of diffuse type GC patients that have a high risk of poor clinical behavior.

2020-03-18 | GSE113255 | GEO

Proteomic signatures of diffuse and intestinal subtypes of gastric cancer

Project description:Gastric cancer is a leading cause of death from cancer globally. Gastric cancer is classified into intestinal, diffuse and indeterminate subtypes based on histology according to the Laurén classification. The intestinal and diffuse subtypes, although different in histology, demographics and outcomes, are still treated in the same fashion. This study was designed to discover proteomic signatures of diffuse and intestinal subtypes. Mass spectrometry-based proteomics using tandem mass tags (TMT)-based multiplexed analysis was used to identify proteins in tumor tissues from patients with diffuse or intestinal gastric cancer with adjacent normal tissue control. A total of 7,804 or 5,166 proteins were identified from intestinal or diffuse subtype, respectively. This quantitative mass spectrometric analysis defined a proteomic signature of differential expression across the two subtypes, which included gremlin1 (GREM1), bcl-2-associated athanogene 2 (BAG2), olfactomedin 4 (OLFM4), thyroid hormone receptor interacting protein 6 (TRIP6) and melanoma-associated antigen 9 (MAGE-A9) proteins. Although GREM1, BAG2, OLFM4, TRIP6 and MAGE-A9 have all been previously implicated in tumor progression and metastasis, they have not been linked to intestinal or diffuse subtypes of gastric cancer. Using immunohistochemical labelling of a tissue microarray comprising of 132 cases of gastric cancer, we validated the proteomic signature obtained by mass spectrometry in the discovery cohort. Our findings should help investigate the pathogenesis of these gastric cancer subtypes and potentially lead to strategies for early diagnosis and treatment.

2022-02-17 | PXD026279 | Pride

Molecular analysis of gastric cancer identifies discrete subtypes associated with distinct clinical characteristics and survival outcomes: the ACRG (Asian Cancer Research Group) study [gastric tumors]

Project description:Gastric cancer, a leading cause of cancer related deaths, is a heterogeneous disease, with little consensus on molecular subclasses and their clinical relevance. We describe four molecular subtypes linked with distinct patterns of molecular alterations, disease progression and prognosis viz. a) Microsatellite Instable: hypermutated intestinal subtype tumors occurring in antrum, best overall prognosis, lower frequency of recurrence (22%), with liver metastasis in 23% of recurred cases b) Mesenchymal-like: diffuse tumors with worst prognosis, a tendency to occur at an earlier age and highest recurrence (63%) with peritoneal seeding in 64% of recurred cases, low frequency of molecular alterations c) TP53-inactive with TP53 loss, presence of focal amplifications and chromosomal instability d) TP53-active marked by EBV infection and PIK3CA mutations. The key molecular mechanisms and associated survival patterns are validated in multiple independent cohorts, to provide a consistent and unified framework for further preclinical and clinical research. ACRG Gastric cohort: microarray profiles from 300 gastric tumors from gastric cancer patients.

2015-04-17 | E-GEOD-62254 | biostudies-arrayexpress

Expression data from intestinal-type and diffuse-type gastric cancers

Project description:To identify the specific genes for intestinal-type and diffuse-type gastric cancers. We selected 18 intestinal-type gastric cancers and 12 diffuse-type gastric cancers showing typical characteristics on the form of cell growth (clustered or scattered) and the degree of differentiation (well/moderate or poor), and performed microarray analysis for obtaining genome-wide mRNA expression profiles.

2014-12-25 | E-GEOD-47007 | biostudies-arrayexpress

Phospho-proteomics enables classification of cancer subtypes and nomination of druggable kinases for individual patients of diffuse-type gastric cancer

Project description:The diffuse-type gastric cancer (DGC) constitutes a subgroup of gastric cancer with poor prognosis and no effective molecular therapies. Here, we report a phosphoproteomic landscape of DGC derived from 83 tumors together with their nearby tissues. Based on phosphorylation, DGC could be classified into three molecular subtypes with distinct overall survival (OS) and chemosensitivity. We identified 16 kinases whose activities were associated with poor OS. These activated kinases covered several cancer hallmark pathways, with the MTOR signaling network being the most frequently activated. We proposed a patient-specific strategy based on the hierarchy of clinically actionable kinases for prioritization of kinases for further clinical evaluation. Our global data analysis indicates that in addition to finding activated kinase pathways in DGC, large-scale phosphoproteomics could be used to classify DGCs into subtypes that are associated with distinct clinical outcomes as well as nomination of kinase targets that may be inhibited for cancer treatments.

2020-03-31 | PXD018293 |

Expression data from intestinal-type and diffuse-type gastric cancers

Project description:To identify the specific genes for intestinal-type and diffuse-type gastric cancers.

2014-12-25 | GSE47007 | GEO

RNA sequencing data for diffuse gastric cancer

Project description:To identify altered transcriptomic profiles in early-onset diffuse gastric cancer (DGC), we performed RNA sequencing on DGCs collected from 80 young (≤ 45 years) Korean patients who had not been treated with chemotherapy or radiation

2018-11-01 | GSE110875 | GEO

Molecular subtypes in gastric cancer.

Project description:Molecular subtypes in gastric cancer.

| PRJNA329144 | ENA

Molecular subtypes in gastric cancer. [II]

Project description:We identified the molecular subtypes and conserved modules in gastric cancer by unsupervised clustering algorithm. We defined five molecular subtypes and six molecular signatrues of gastric cancer associated with the biological heterogeneity of gastric cancer and clinical outcome of patients.

2018-03-20 | GSE84433 | GEO

Molecular subtypes in gastric cancer. [I]

2018-03-20 | GSE84426 | GEO